iOnctura Raises EUR80M in Funding to Accelerate Cancer Treatment Development

iOnctura Raises EUR80M in Series B Funding

iOnctura (Linkedin), a biotechnology research company based in Switzerland, has secured EUR80M in Series B funding to accelerate the development of their precision oral small molecule, roginolisib. With a focus on neglected and hard-to-treat cancers, iOnctura aims to provide innovative treatment options for patients.

Funding Amount: EUR80 million

Industry: Biotechnology Research

Employee Count: 11-50

CEO: Catherine Pickering (CEO Linkedin)

What iOnctura needs to buy: iOnctura is seeking partnerships with clinical research organizations, manufacturers, suppliers, marketing agencies, and sales experts. Companies specializing in precision cancer treatments, clinical trial services, manufacturing and supply chain solutions, and marketing and sales support are well-positioned to collaborate with iOnctura in advancing their innovative cancer treatments.